Formation of high-affinity C5 convertases of the alternative pathway of complement

被引:68
作者
Rawal, N [1 ]
Pangburn, MK [1 ]
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75708 USA
关键词
D O I
10.4049/jimmunol.166.4.2635
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cleavage of C5 by C5 convertase is the last enzymatic step in the complement activation cascade leading to the formation of the cytolytic proteolytically activated form of C5 (C5b)-9 complex, In the present study, we examined the effect of the density of C3b (the proteolytically activated form of C3) on the function of the noncatalytic subunit of natural surface-bound forms of the enzyme. A comparison of the kinetic parameters of C5 convertases assembled on three surfaces (zymosan, rabbit erythrocytes, and sheep erythrocytes) were similar and revealed that the average K-m decreased similar to 28-fold (5.2-0.18 muM) when the density of C3b was increased from similar to 18,000 to 400,000 C3b/cell. Very-high-affinity C5 convertases were generated when preformed C3 convertases were allowed to self amplify by giving them excess C3. These convertases exhibited K-m from 0.016 to 0.074 muM, well below the normal plasma concentration of C5 in blood (0.37 muM). The results suggest that in serum convertases formed with monomeric C3b will be relatively inefficient in capturing C5 but,will continue to cleave C3 opsonizing the cell surface for phagocytosis, whereas convertases formed with C3b-C3b complexes in areas of high C3b density will primarily cleave C5. The catalytic rate of these convertases approaches maximum velocity, thereby switching the enzyme from cleavage of C3 to cleavage of C5, and production of the cytolytic C5b-9 complex.
引用
收藏
页码:2635 / 2642
页数:8
相关论文
共 33 条
[1]  
CHRISTOPHERSON RI, 1983, METHOD ENZYMOL, V91, P278
[2]  
DAHA MR, 1976, J IMMUNOL, V117, P630
[3]  
DIAS DS, 1967, J EXP MED, V125, P921
[6]  
Ember J., 1998, The Human Complement System in Health and Disease, P241
[7]  
GOTZE O, 1971, J EXP MED, V134, pS90
[8]  
HAMMER CH, 1981, J BIOL CHEM, V256, P3995
[9]  
HONG KS, 1991, J IMMUNOL, V146, P1868
[10]  
ISENMAN DE, 1980, J IMMUNOL, V124, P326